Sponsor

2012/07/05

What Obamacare Means to Your Portfolio

Investment U Daily - Turning Principles Into Profits
Issue Number #1810


Investment U Today
  • » Marc Lichtenfeld analyzes the effects of Obamacare...
  • » Alexander Green sees one sector as the hottest for 2012...
  • » How does the Moody's downgrade affect banks?
  • » Special: Join our network of top financial experts...

What Obamacare Means to Your Portfolio
by Marc Lichtenfeld, Investment U Senior Analyst
Thursday, July 5, 2012
I was bleary eyed as the line I was standing in snaked halfway across JFK International Airport. I had just gotten off my eight-hour flight from Stockholm when in the distance I saw a TV tuned to CNN. The sound was off and I could barely make out the graphics, but I thought it said something about the Supreme Court ruling on the Affordable Care Act.

I tried to look up the info on my phone, but got yelled at by a customs officer. For some reason, you're not allowed to use your phone while waiting in line. I wanted to protest, but I thought better of getting into an argument with a customs officer. Cavity searches are not my bag, baby!

Eventually, I was close enough to the TV to make out the graphics that the Supreme Court upheld the President's healthcare reform law. I had no idea how the market or healthcare stocks were reacting. And I wasn't going to risk another altercation with Big Bertha (the name I secretly gave the customs officer).

Once I finally cleared customs, I tried to log on to the internet on my phone, but the airport's Boingo Wi-Fi service jammed it. I finally got hold of a hedge fund manager friend of mine in California who gave me the details.
---------- Advertisement ----------
Start Putting this Moneymaking Research to Work for You

To get top-tier investment research - the kind that could be used to score big gains in any market - you'd normally have to pay anywhere from $150... to $4,500... or higher. But what if I told you that you can get some of this same moneymaking intelligence for under $5? Even better, what if you could get access just seconds from now?

It's all possible, thanks to a newly-discovered loophole. Click here to learn more.
-----------------------------------------
I barely had time to digest the information when I had to get on another flight down to Florida.

But now that a few days have passed, I've had time to go through the news, see how stocks have reacted and analyze the situation...

The Biggest Winners: Hospitals

I expect the biggest winners to be hospitals, because of the likelihood of higher reimbursement rates.

More patients with insurance means fewer indigent and Medicaid patients. The patients who enjoy a weeklong hospital stay and then never pay a dime are the reason it costs you and me $60 for a Tylenol. Additionally, private insurance typically pays a much higher rate than Medicaid, so those dollars should flow right to the hospitals' bottom lines. A hospital's cost is basically the same (except for perhaps some administrative costs) whether they're treating a patient with great insurance or none at all.

In fact, one hospital stock that I recommended in my FirstLine Investor Alert took off after the ruling. The company, which I'm recommending in today's Investment U Plus, owns 70 hospitals in 15 states and saw its stock price jump roughly 15% since the news came out.

Are Medicaid Stocks in Trouble?

There's some skepticism on Wall Street about the Medicaid insurers like Molina Healthcare (NYSE: MOH), because the Court ruled that states could opt out of the Medicaid expansion that's part of the law.

Under the Affordable Care Act, individuals who make less than $19,157 per year or a family of four who makes below $30,656 are eligible for Medicaid. The Federal government will pick up the full tab from 2014 to 2016. After that, states will be responsible for up to 10% of the cost.

Some states, primarily those with outspoken Republican governors, have said they will not participate in the Medicaid expansion, because it'll cost the states too much money in the long run.

Even if that occurs, the Medicaid insurers won't be negatively impacted. They simply won't get the benefit of the expansion. Nothing is being taken away, it just won't get added.

Just Say "Yes" to Drugs

Pharmaceutical and biotech companies should also benefit as 33 million more insured patients means more customers buying drugs. Bristol-Myers Squibb (NYSE: BMY) has been my favorite large pharma for a long time and is part of The Ultimate Income Letter's Perpetual Income Portfolio. Bristol currently has a yield of 3.9% and has some exciting and promising new drugs including Yervoy, the first drug ever to show a benefit for patients with metastatic melanoma.

Biotech companies also benefited from the ruling as the law includes a 12-year period of marketing exclusivity for biologics.

One of the few groups in healthcare that won't see much of a benefit is the medical device industry. There may be a small uptick in patients, but the typical user of a medical device is over 65 and thus already on Medicare. Additionally, medical device companies are now required to pay a 2.3% tax starting next year.

Love it or hate it, the Affordable Care Act is likely here to stay. Even if Mitt Romney wins in November, it's unlikely that Republicans will take enough seats in the Senate to overturn the law.

So if you want to insure that your portfolio is healthy, start looking at some hospital, pharmaceutical and biotech companies to hold for the long term. The new law will impact top and bottom lines of these companies for years to come.

Good Investing,

Marc Lichtenfeld



More from Investment U...
The Hottest Stock Market Sector in 2012

Too many investors are focused on high unemployment, weak economic growth, problems in the Eurozone and runaway deficit spending. They seldom note the positives, including low inflation, rock-bottom interest rates, falling food and energy prices (coal and natural gas), expanding opportunities in emerging markets, low valuations and - not least of all - all-time record corporate profits.

So don't let the doomsayers get you down. There are always opportunities out there, even during the most difficult economic times...

Click here for the full story
EXPOSED: Mainstream Medicine's Deadliest Conspiracy

Can you believe this video? It's a phenomenon. In fact, it was sent to more than 289,000 people in just the first 24 hours!

But you might not see it at all.

Why? Because, for the first time, mainstream medicine's deadliest conspiracy has been EXPOSED. Finally, this video is the "shot heard around the world" the establishment prayed would never come.

There are powerful interests hell-bent on minimizing the damage it is doing to corporate medicine's profit machine.

Before it's banned...

Click here for the full story
The Moody's Downgrade: Hurts Some Banks, but Helps Others

A new trend that evolved after the banking crisis is weaker banks with less "shock absorbers" getting hammered for taking risk. Meanwhile, stronger banks are rewarded for being more conservative, guaranteeing lower costs and greater margins.

Those banks with lower ratings will not only see their cost of business increasing, but could see trading partners ask for more collateral...

Click here for the full story







Related Articles:
 

~ SHARE INVESTMENT U ~
If you enjoy reading Investment U, why not share it with your family and friends?
Simply send them this link, so they can sign up (for free, of course).

Find the Print Version for this Issue, here.

~ QUESTIONS ~
Republish Investment U on your Website or blog for free. Learn how.
Have a question for our editorial team? Contact us.


© 2012 Investment U All Rights Reserved
Investment U · 105 West Monument Street · Baltimore, MD 21201
North America: 1 855 402 3939; Fax: 1 410 223 2650 International: +1 410 226 2070; Fax: +1 410 223 2650
E-mail: CustomerService@InvestmentUInfo.com | Website: www.InvestmentU.com
Disclaimer Information
and Privacy Policy

Note: You are receiving this e-mail as a part of your free subscription to Investment U.
Keep the e-mails you value from falling into your spam folder, Whitelist Investment U

To manage your account or stop receiving Investment U, click here.
To cancel by mail or for any other subscription issues, write us at:
Investment U · Attn: Member Services · 105 West Monument Street · Baltimore, MD 21201

Nothing in this e-mail should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investment advice.

We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.

You're receiving this message because you subscribe to the Investment U e-letter. If you wish to post a comment on any of our articles, or contact our Customer Service team, please see the instructions above. Do not reply directly to this e-mail, as your message will not be read or answered. Also, please keep in mind that securities laws prevent us from issuing personal investment advice to our readers. We're prohibited from answering such questions or giving that information via e-mail or over the phone.

Protected by copyright laws of the United States and international treaties. This Newsletter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Investment U. 105 W. Monument Street, Baltimore MD 21201

No comments:

Post a Comment

Keep a civil tongue.

Label Cloud

Technology (1464) News (793) Military (646) Microsoft (542) Business (487) Software (394) Developer (382) Music (360) Books (357) Audio (316) Government (308) Security (300) Love (262) Apple (242) Storage (236) Dungeons and Dragons (228) Funny (209) Google (194) Cooking (187) Yahoo (186) Mobile (179) Adobe (177) Wishlist (159) AMD (155) Education (151) Drugs (145) Astrology (139) Local (137) Art (134) Investing (127) Shopping (124) Hardware (120) Movies (119) Sports (109) Neatorama (94) Blogger (93) Christian (67) Mozilla (61) Dictionary (59) Science (59) Entertainment (50) Jewelry (50) Pharmacy (50) Weather (48) Video Games (44) Television (36) VoIP (25) meta (23) Holidays (14)

Popular Posts (Last 7 Days)